{"id":"immunoglobulin-perfusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Local tissue reactions at perfusion site"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach uses regional perfusion techniques to deliver immunoglobulins (antibodies) at high concentrations directly to target tissues, bypassing systemic circulation limitations. By achieving elevated local antibody levels, the therapy aims to enhance immune-mediated destruction of pathological cells or pathogens while potentially reducing systemic exposure and adverse effects.","oneSentence":"Immunoglobulin perfusion delivers immunoglobulins directly to affected tissues via regional perfusion to enhance local immune response and antibody concentration.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:46.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Investigational indication in phase 3 (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT05681884","phase":"PHASE2","title":"Safety and Efficacy of Faricimab in Patients With NPDR","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2023-05-16","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":179},{"nctId":"NCT04283890","phase":"PHASE1, PHASE2","title":"PHP and Immunotherapy in Metastasized UM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2019-12-04","conditions":"Uveal Melanoma, Metastatic","enrollment":83},{"nctId":"NCT03700138","phase":"PHASE3","title":"Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-06-19","conditions":"Primary Sjögren's Syndrome Painful Sensory Neuropathies","enrollment":24},{"nctId":"NCT06906549","phase":"PHASE4","title":"Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-07-11","conditions":"Rheumatoid Arthritis (RA), Rituximab (RTx)","enrollment":260},{"nctId":"NCT07075562","phase":"NA","title":"TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2021-06-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":180},{"nctId":"NCT04463368","phase":"PHASE1","title":"Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2021-03-08","conditions":"Uveal Melanoma, Liver Metastases","enrollment":18},{"nctId":"NCT04444492","phase":"PHASE3","title":"Combination of Ranibizumab and Targeted Laser Photocoagulation","status":"RECRUITING","sponsor":"University of Giessen","startDate":"2020-08-25","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":110},{"nctId":"NCT03102125","phase":"PHASE4","title":"Allograft Dysfunction in Heart Transplant","status":"RECRUITING","sponsor":"Paul Kim","startDate":"2019-10-01","conditions":"Heart Transplant Failure and Rejection","enrollment":376},{"nctId":"NCT06519266","phase":"PHASE3","title":"PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2024-06-10","conditions":"Uveal Melanoma, Liver Metastases","enrollment":40},{"nctId":"NCT06041477","phase":"PHASE3","title":"Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-31","conditions":"Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":540},{"nctId":"NCT06405061","phase":"PHASE2","title":"Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-05-01","conditions":"Adebrelimab, Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05682196","phase":"PHASE2","title":"Rituximab in Patients With Acute Rheumatic Fever","status":"SUSPENDED","sponsor":"African Academy of Methodology and Statistics","startDate":"2023-01-05","conditions":"Rheumatic Heart Disease in Children","enrollment":234},{"nctId":"NCT03685890","phase":"PHASE1, PHASE2","title":"Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2019-04-01","conditions":"Melanoma, In-Transit Metastasis","enrollment":74},{"nctId":"NCT03704610","phase":"PHASE3","title":"Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-03-28","conditions":"Extrathoracic Sarcoidosis","enrollment":31},{"nctId":"NCT04674254","phase":"PHASE4","title":"Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-03-30","conditions":"Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy","enrollment":43},{"nctId":"NCT05742425","phase":"PHASE2","title":"Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03","conditions":"Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type","enrollment":30},{"nctId":"NCT04991350","phase":"PHASE4","title":"Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Cairo University","startDate":"2021-11-26","conditions":"Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy","enrollment":5},{"nctId":"NCT05701124","phase":"PHASE3","title":"Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-11-20","conditions":"Retina Disease, Retinopathy of Prematurity, Ranibizumab","enrollment":30},{"nctId":"NCT02769689","phase":"PHASE4","title":"Methylprednisolone During the Switch Between Natalizumab and Fingolimod","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-12","conditions":"Multiple Sclerosis","enrollment":56},{"nctId":"NCT03388008","phase":"PHASE2","title":"Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-12-17","conditions":"Lung Transplant Rejection, Antibody-mediated Rejection","enrollment":27},{"nctId":"NCT04507477","phase":"PHASE1, PHASE2","title":"Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-07-07","conditions":"Epstein-Barr Virus Infections, Post-transplant Lymphoproliferative Disorder","enrollment":10},{"nctId":"NCT05386160","phase":"PHASE4","title":"Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-07-01","conditions":"Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy","enrollment":96},{"nctId":"NCT01213732","phase":"PHASE1","title":"Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma","status":"COMPLETED","sponsor":"Philogen S.p.A.","startDate":"2008-10","conditions":"Patients With Intransit Stage III/IV Melanoma","enrollment":19},{"nctId":"NCT02843230","phase":"","title":"Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-08-01","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT02076152","phase":"NA","title":"FMISO PET Study of Glioblastoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-02","conditions":"Recurrent Glioblastoma","enrollment":11},{"nctId":"NCT01557374","phase":"PHASE4","title":"TOward the Lowest Effective DOse of Abatacept or Tocilizumab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-04","conditions":"Rheumatoid Arthritis","enrollment":232},{"nctId":"NCT01443065","phase":"PHASE2","title":"MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2011-01","conditions":"Malignant Neoplasm of Esophagus, Malignant Neoplasm of Stomach","enrollment":162},{"nctId":"NCT03154385","phase":"NA","title":"Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-03-13","conditions":"Immune Thrombocytopenia","enrollment":15},{"nctId":"NCT03246152","phase":"PHASE4","title":"Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-10-23","conditions":"Diabetic Macular Edema, Ischemic Maculopathy","enrollment":31},{"nctId":"NCT03433534","phase":"","title":"Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2018-01-29","conditions":"Kidney Cancer, Lung Cancer","enrollment":64},{"nctId":"NCT04062370","phase":"PHASE4","title":"Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-01","conditions":"Retinal Vein Occlusion, Treatment, Photocoagulation Burn to Retina","enrollment":100},{"nctId":"NCT01142778","phase":"PHASE2","title":"A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-19","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT00782756","phase":"PHASE2","title":"Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-10-28","conditions":"Brain Cancer, Malignant Glioma","enrollment":40},{"nctId":"NCT03377283","phase":"PHASE4","title":"Peri-operative rATG-perfusion of Solid Transplants","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2012-08-17","conditions":"Organ Preservation Solutions","enrollment":80},{"nctId":"NCT00381797","phase":"PHASE2","title":"Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-08","conditions":"Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm","enrollment":97},{"nctId":"NCT01710839","phase":"PHASE4","title":"Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Charles C Wykoff, PhD, MD","startDate":"2012-10","conditions":"Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions","enrollment":30},{"nctId":"NCT03195569","phase":"","title":"To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2017-03-01","conditions":"Non Small Cell Lung Cancer","enrollment":15},{"nctId":"NCT03193086","phase":"","title":"The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2017-01-01","conditions":"Multiple Sclerosis","enrollment":35},{"nctId":"NCT01731457","phase":"PHASE2","title":"Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2011-04","conditions":"Transplanted Kidney Ischemia Reperfusion Injury","enrollment":94},{"nctId":"NCT02841332","phase":"NA","title":"Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma","status":"TERMINATED","sponsor":"University Hospital, Toulouse","startDate":"2013-05","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT02867553","phase":"PHASE3","title":"Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions","status":"UNKNOWN","sponsor":"CHU de Reims","startDate":"2011-10","conditions":"Indolent Cutaneous B Cell Lymphomas","enrollment":36},{"nctId":"NCT02094391","phase":"PHASE2","title":"Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2014-03","conditions":"In-transit Metastases Melanoma Stage IIIB and IIIC","enrollment":4},{"nctId":"NCT01442025","phase":"PHASE4","title":"Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2012-06","conditions":"Crohn's Disease","enrollment":121},{"nctId":"NCT01148901","phase":"PHASE4","title":"Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06","conditions":"Ankylosing Spondylitis","enrollment":""},{"nctId":"NCT00709657","phase":"NA","title":"The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2008-03","conditions":"Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor","enrollment":8},{"nctId":"NCT01349270","phase":"PHASE3","title":"Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2004-06","conditions":"Demyelinating Polyneuropathy","enrollment":40},{"nctId":"NCT00525616","phase":"PHASE3","title":"Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2008-12","conditions":"Bullous Pemphigoid","enrollment":18},{"nctId":"NCT01198327","phase":"PHASE3","title":"Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Peter A Campochiaro, MD","startDate":"2010-08","conditions":"Retinal Vein Occlusion","enrollment":66},{"nctId":"NCT01838538","phase":"PHASE2","title":"Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2011-06","conditions":"Ovarian Cancer With Malignant Ascites","enrollment":54},{"nctId":"NCT00373451","phase":"PHASE4","title":"Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2006-07","conditions":"Myocardial Infarction, Coronary Disease","enrollment":1721},{"nctId":"NCT00927615","phase":"NA","title":"Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2008-09","conditions":"ST-Elevation Myocardial Infarction","enrollment":534},{"nctId":"NCT00664599","phase":"PHASE2","title":"Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2006-04","conditions":"Behcet's Syndrome","enrollment":20},{"nctId":"NCT00169819","phase":"PHASE4","title":"EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study","status":"COMPLETED","sponsor":"Laval University","startDate":"2003-10","conditions":"Coronary Artery Disease, Ischemia","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2550,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Immunoglobulin perfusion","genericName":"Immunoglobulin perfusion","companyName":"Centre Hospitalier Universitaire de Saint Etienne","companyId":"centre-hospitalier-universitaire-de-saint-etienne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Immunoglobulin perfusion delivers immunoglobulins directly to affected tissues via regional perfusion to enhance local immune response and antibody concentration. Used for Investigational indication in phase 3 (specific indication not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}